Neonatal respiratory distress syndrome

Neonatal Respiratory Distress Syndrome (NRDS), also known as Infant Respiratory Distress Syndrome (IRDS), is a serious medical condition primarily affecting premature infants. This syndrome is characterized by the inability of a newborn to breathe adequately due to the lack of a slippery substance in the lungs called surfactant. Surfactant is crucial for keeping the air sacs (alveoli) in the lungs open, allowing for the exchange of oxygen and carbon dioxide in the blood. NRDS is a leading cause of morbidity and mortality in preterm infants.

Causes and Risk Factors

The primary cause of NRDS is the immaturity of the lungs, which results in insufficient production of surfactant. The risk of developing NRDS increases with the degree of prematurity; the more premature the infant, the higher the risk. Other factors that may contribute to the risk of NRDS include:

• A family history of the condition
• Maternal diabetes
• Cesarean delivery without labor
• Second-born twin or other multiple birth

Pathophysiology

Surfactant production in the fetus begins around the 24th to 28th week of pregnancy and is usually adequate by 34 to 36 weeks. In infants with NRDS, the lack of surfactant leads to alveolar collapse, resulting in compromised gas exchange and hypoxemia (low blood oxygen levels). This can lead to acidosis and further inhibit surfactant production, creating a cycle that is difficult to break without intervention.

Symptoms

Symptoms of NRDS typically appear within the first few hours after birth and may include:

• Rapid, shallow breathing
• Grunting sounds with breathing
• Nasal flaring
• Chest retractions (pulling in of the ribs and sternum during breathing)
• Cyanosis (a bluish color of the skin, lips, and nail beds)

Diagnosis

Diagnosis of NRDS is based on the clinical presentation and history of the infant, including the degree of prematurity. Chest X-rays can reveal a characteristic "ground glass" appearance of the lungs, indicative of NRDS. Blood tests to check oxygen and carbon dioxide levels may also be performed.

Treatment

Treatment for NRDS focuses on supporting the infant's breathing and ensuring adequate oxygenation. This may include:

• Administration of supplemental oxygen
• Mechanical ventilation for severe cases
• Surfactant replacement therapy, where artificial surfactant is administered into the infant's lungs
• Supportive care, including maintaining the infant's body temperature and ensuring proper nutrition

Prevention

Preventive measures for NRDS include the administration of corticosteroids to pregnant women at risk of preterm delivery. These medications can accelerate lung maturation and surfactant production in the fetus, reducing the risk of NRDS.

Prognosis

With advances in neonatal care, the prognosis for infants with NRDS has significantly improved. However, the condition can still lead to complications such as Bronchopulmonary Dysplasia (BPD), Patent Ductus Arteriosus (PDA), and intraventricular hemorrhage. Early diagnosis and treatment are crucial for a favorable outcome.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian